Enhanced adoptive cell therapy
Application
US20260078349A1
Kind: A1
Mar 19, 2026
Inventors
Akseli Hemminki, Markus Vähä-Koskela, Siri Tähtinen, Vincenzo Cerullo
Abstract
The present invention relates to the fields of life sciences and medicine. Specifically, the invention relates to cancer therapies of humans. More specifically, the present invention relates to oncolytic adenoviral vectors alone or together with therapeutic compositions for therapeutic uses and therapeutic methods for cancer. In one aspect the present invention relates to separate administration of adoptive cell therapeutic composition and oncolytic adenoviral vectors. Furthermore, the present invention relates to a pharmaceutical kit and a pharmaceutical composition, both utilizing oncolytic adenoviral vectors.
CPC Classifications
C12N 7/00
A61K 35/17
A61K 35/76
A61K 35/761
A61K 40/11
A61K 40/32
A61K 40/42
C07K 14/472
C07K 14/52
C07K 14/525
C07K 14/55
C07K 14/565
C07K 14/57
C12N 15/86
A61K 2035/124
A61K 48/00
A61K 2239/38
A61K 2239/57
C12N 2710/10032
C12N 2710/10041
C12N 2710/10043
Filing Date
2025-09-16
Application No.
19329926